Shares in Australian biopharmaceutical company Mesoblast jumped 25 per cent after Revascor was recognised as a potential treatment for heart disease in babies.
After another knockback from the US regulator, its sceptics say it’s business as usual. And Mesoblast chief executive Silviu Itescu remains as optimistic as ever.
Willem Blijdorp, chairman of the ASX-listed biotech and one of the Netherlands’ wealthiest entrepreneurs, is accused of extortion and forgery relating to Iranian marble quarries.
Push to kneecap super proxy advisers
Apr 30, 2021 – 9.30pm
Share
The influential advisory firm controlled by the $500 billion industry super fund sector would be kneecapped under a push by Treasurer Josh Frydenberg to regulate the way institutional shareholders vote on how companies deal with environmental, social and governance issues.
The proposed measures include forcing proxy advisers to give the companies they are reviewing a week’s notice of how they are recommending shareholders should vote and the research on which it is based. Firms would also have to give clients access to the company’s response.
Australian Council of Superannuation Investors president Ian Silk with chief executive Louise Davidson.